INTRODUCTION AND OBJECTIVES: Active Surveillance (AS)
is increasingly utilized to manage very-low (VLR), low (LR), and some favorable intermediate risk (IR) prostate cancer (PCa). Most studies examining AS outcomes have been based on standard 12-core systematic biopsies (SB). We examined the outcomes of patients who were selected for AS after undergoing multi-parametric magnetic resonance imaging (mpMRI) with fusion guided biopsies (FB) of MRIdetected lesions in addition to SB.
METHODS: A retrospective review was conducted of all patients with Gleason Grade Group (GG) 1 (Gleason Score 3þ3) or 2 (Gleason Score 3þ4) PCa managed initially with AS. Kaplan-Meier graphs were constructed to determine the time patients continued AS and time for GG progression free-survival (PFS). Cox proportions hazard regression was performed to determine factors significant for GG progression. Those who underwent radical prostatectomy had their final pathology examined for adverse pathology (GG>2 or !T3 disease) RESULTS: 246 (172 GG 1 and 74 GG 2) patients met inclusion criteria. The median time remaining on AS for the GG 1 group was not reached (although nearing 96 months) and for the GG 2 group was 53.88 months, p<0.01. Median time for GG PFS for the GG 1 and GG 2 groups were 57.27 and 45.11 months, respectively, p[0.03. Significant variables for progression included age (HR 1.05 95% CI 1.01-1.09, p<0.01), PSA density (HR 1.03 95% CI 1.01-1.09, p[0.01, size of the largest lesion on mpMRI (HR 1.66 95% CI 1.07-2.57, p[0.02) and the number of targeted biopsy cores positive for cancer (HR 1.24 95% CI 1.03-1.50, p[0.02). None of the AS patients who went on to RP had positive margins or lymph nodes. AP occurred in 3/18 (16.7%) of patients starting with GG 2 disease.
CONCLUSIONS: mpMRI-directed FB provides an effective way to select and monitor patients with LR PCa on AS. This additional information helps in predicting which patients will progress on AS. METHODS: From 01/2016 to 09/2018, 340 pts underwent mpMRI before confirmatory/follow-up biopsy according to PRIAS protocol. Pts with negative (-) mpMRI received systematic random biopsy. Pts with positive (þ) mpMRI (PI-RADS score [>3) underwent targeted biopsies (3 cores) þ systematic random biopsies (12-18 cores). Multivariate logistic regression analyses (MVA) was used to create 3 model predicting the probability of disease reclassification (PCa GS [>3þ4 at biopsy): a basic model including only clinical variables (age, PSAD and number (#) of positive cores at baseline); a MRI model including only PI-RADS score; a full model including both the previous ones. The predictive accuracy (PA) of each model was quantified using the AUC. The clinical net benefit deriving from the use of each model was assessed with decision curve analysis.
RESULTS: Median patient age, PSA and PSAD were 67 yrs, 6.3 ng/ml, and 0.12 ng/ml/cm3. Median # of positive cores at initial biopsy was 1 (IQR:1,2). Eighty-four pts (24.7%) had mpMRI(-); 71 pts (20.9%), 146 (42.9%), and 39 (11.5%) had PI-RADS 3,4, and 5 lesions, respectively. At a median follow up of 12 months, 113 patients (33.2%) were reclassified. In pts with mpMRI(-) the rate of reclassification was 18%. while was 28%, 40% and 50% according to PI-RADS 3, 4 and 5, respectively. In the basic model, PSAD and # of positive cores at baseline were independent predictors of reclassification (p[0.001; OR 66.4 and p<0.001; OR 2.2, respectively) , with a PA of 69%. In the MRI model, PI-RADS 5 was predictor of reclassification (p[0.002; OR 4.7) and the PA was lower than in the basic model (AUC 62%). The full model had the best PA of 72%. PSAD (p[0.01; OR 28.6), # of positive cores at baseline (p<0.001; OR 2.2) and PI-RADS 5 (p[0.02; OR 3.6) were predictors of reclassification. Fig.1 depicts clinical net benefit deriving from the use of the three evaluated models.
CONCLUSIONS: MRI alone should not be used in clinical practice as a stand-alone trigger for disease reclassification. The combination of MRI and other clinical variables still represents the most accurate approach to patients on AS. 
